These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 18617335)

  • 1. Assessment of efficacy of a bivalent BTV-2 and BTV-4 inactivated vaccine by vaccination and challenge in cattle.
    Savini G; Hamers C; Conte A; Migliaccio P; Bonfini B; Teodori L; Di Ventura M; Hudelet P; Schumacher C; Caporale V
    Vet Microbiol; 2009 Jan; 133(1-2):1-8. PubMed ID: 18617335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines against bluetongue in Europe.
    Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An inactivated vaccine for the control of bluetongue virus serotype 16 infection in sheep in Italy.
    Savini G; Ronchi GF; Leone A; Ciarelli A; Migliaccio P; Franchi P; Mercante MT; Pini A
    Vet Microbiol; 2007 Sep; 124(1-2):140-6. PubMed ID: 17499459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep.
    Hamers C; Rehbein S; Hudelet P; Blanchet M; Lapostolle B; Cariou C; Duboeuf M; Goutebroze S
    Vaccine; 2009 May; 27(21):2789-93. PubMed ID: 19366576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of cattle using monovalent modified-live vaccine against bluetongue virus serotype 2: innocuity, immunogenicity and effect on pregnancy.
    Monaco F; Bonfini B; Zaghini M; Antonucci D; Pini A; Savini G
    Vet Ital; 2004; 40(4):671-5. PubMed ID: 20422610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats.
    Bréard E; Belbis G; Hamers C; Moulin V; Lilin T; Moreau F; Millemann Y; Montange C; Sailleau C; Durand B; Desprat A; Viarouge C; Hoffmann B; de Smit H; Goutebroze S; Hudelet P; Zientara S
    Vaccine; 2011 Mar; 29(13):2495-502. PubMed ID: 21256877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus.
    Barros SC; Cruz B; Luís TM; Ramos F; Fagulha T; Duarte M; Henriques M; Fevereiro M
    Vet Microbiol; 2009 Jun; 137(3-4):252-9. PubMed ID: 19233575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monovalent modified-live vaccine against bluetongue virus serotype 2: immunity studies in cows.
    Savini G; Monaco F; Citarella R; Calzetta G; Panichi G; Ruiu A; Caporale V
    Vet Ital; 2004; 40(4):664-7. PubMed ID: 20422608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep.
    Eschbaumer M; Hoffmann B; König P; Teifke JP; Gethmann JM; Conraths FJ; Probst C; Mettenleiter TC; Beer M
    Vaccine; 2009 Jun; 27(31):4169-75. PubMed ID: 19406189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of adaptive immune responses and heterologous protection induced by inactivated bluetongue virus vaccines.
    Breard E; Belbis G; Viarouge C; Nomikou K; Haegeman A; De Clercq K; Hudelet P; Hamers C; Moreau F; Lilin T; Durand B; Mertens P; Vitour D; Sailleau C; Zientara S
    Vaccine; 2015 Jan; 33(4):512-8. PubMed ID: 25500308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety studies on an inactivated vaccine against bluetongue virus serotype 2.
    Di Emidio B; Nicolussi P; Patta C; Ronchi GF; Monaco F; Savini G; Ciarelli A; Caporale V
    Vet Ital; 2004; 40(4):640-4. PubMed ID: 20422602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers.
    van der Sluijs MT; Schroer-Joosten DP; Fid-Fourkour A; Vrijenhoek MP; Debyser I; Gregg DA; Dufe DM; Moulin V; Moormann RJ; de Smit AJ
    Vaccine; 2012 Jan; 30(3):647-55. PubMed ID: 22107846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological and serological response of cattle following field vaccination with bivalent modified-live vaccine against bluetongue virus serotypes 2 and 9.
    Monaco F; De Luca N; Spina P; Morelli D; Liberatore I; Citarella R; Conte A; Savini G
    Vet Ital; 2004; 40(4):657-60. PubMed ID: 20422606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralising antibody responses in cattle and sheep following booster vaccination with two commercial inactivated bluetongue virus serotype 8 vaccines.
    Bartram DJ; Heasman L; Batten CA; Oura CA; Plana-Durán J; Yuen HM; Wylie AD
    Vet J; 2011 May; 188(2):193-6. PubMed ID: 20466568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical disease in sheep caused by bluetongue virus serotype 8, and prevention by an inactivated vaccine.
    Moulin V; Noordegraaf CV; Makoschey B; van der Sluijs M; Veronesi E; Darpel K; Mertens PP; de Smit H
    Vaccine; 2012 Mar; 30(12):2228-35. PubMed ID: 22207091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep.
    Oura CA; Wood JL; Sanders AJ; Bin-Tarif A; Henstock M; Edwards L; Floyd T; Simmons H; Batten CA
    Vaccine; 2009 Dec; 27(52):7326-30. PubMed ID: 19786141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colostral antibody protection and interference with immunity in lambs born from sheep vaccinated with an inactivated Bluetongue serotype 8 vaccine.
    Oura CA; Wood JL; Floyd T; Sanders AJ; Bin-Tarif A; Henstock M; Edwards L; Simmons H; Batten CA
    Vaccine; 2010 Mar; 28(15):2749-53. PubMed ID: 20123052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-propiolactone inactivated bivalent bluetongue virus vaccine containing Montanide ISA-71VG adjuvant induces long-term immune response in sheep against serotypes 4 and 16 even after 3 years of controlled vaccine storage.
    Zhugunissov K; Bulatov Y; Taranov D; Yershebulov Z; Koshemetov Z; Zhunushov A; Renukaradhya GJ; Tabynov K; Abduraimov Y
    Vet Microbiol; 2018 Nov; 226():23-30. PubMed ID: 30389040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological and serological response of sheep following field vaccination with bivalent modified-live vaccine against bluetongue virus serotypes 2 and 9.
    Savini G; Monaco F; Conte A; Migliaccio P; Casaccia C; Salucci S; Di Ventura M
    Vet Ital; 2004; 40(4):631-4. PubMed ID: 20422600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.